Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 309

1.

Time resolved amplified FRET identifies protein kinase B activation state as a marker for poor prognosis in clear cell renal cell carcinoma.

Miles J, Applebee CJ, Leboucher P, Lopez-Fernandez S, Lee DJ, Guarch R, Ward S, Parker PJ, López JI, Larijani B.

BBA Clin. 2017 Oct 13;8:97-102. doi: 10.1016/j.bbacli.2017.10.002. eCollection 2017 Dec.

2.

A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib.

O'Shea J, Cremona M, Morgan C, Milewska M, Holmes F, Espina V, Liotta L, O'Shaughnessy J, Toomey S, Madden SF, Carr A, Elster N, Hennessy BT, Eustace AJ.

Oncotarget. 2017 Jul 22;8(49):85120-85135. doi: 10.18632/oncotarget.19461. eCollection 2017 Oct 17.

3.

Hypoxia-induced reactive oxygen species mediate N-cadherin and SERPINE1 expression, EGFR signalling and motility in MDA-MB-468 breast cancer cells.

Azimi I, Petersen RM, Thompson EW, Roberts-Thomson SJ, Monteith GR.

Sci Rep. 2017 Nov 9;7(1):15140. doi: 10.1038/s41598-017-15474-7.

4.

Phosphatidylinositol 3-kinase (PI3Kα)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells.

Morgillo F, Della Corte CM, Diana A, Mauro CD, Ciaramella V, Barra G, Belli V, Franzese E, Bianco R, Maiello E, de Vita F, Ciardiello F, Orditura M.

Oncotarget. 2017 Aug 22;8(44):76479-76491. doi: 10.18632/oncotarget.20385. eCollection 2017 Sep 29.

5.

Resistance mechanisms to genetic suppression of mutant NRAS in melanoma.

Robinson JP, Rebecca VW, Kircher DA, Silvis MR, Smalley I, Gibney GT, Lastwika KJ, Chen G, Davies MA, Grossman D, Smalley KSM, Holmen SL, VanBrocklin MW.

Melanoma Res. 2017 Dec;27(6):545-557. doi: 10.1097/CMR.0000000000000403.

PMID:
29076949
6.

Potential therapeutic targets of triple-negative breast cancer based on its intrinsic subtype.

Shao F, Sun H, Deng CX.

Oncotarget. 2017 Aug 16;8(42):73329-73344. doi: 10.18632/oncotarget.20274. eCollection 2017 Sep 22. Review.

7.

Identification of Linkages between EDCs in Personal Care Products and Breast Cancer through Data Integration Combined with Gene Network Analysis.

Jeong H, Kim J, Kim Y.

Int J Environ Res Public Health. 2017 Sep 30;14(10). pii: E1158. doi: 10.3390/ijerph14101158.

8.

Analysis of ESR1 and PIK3CA mutations in plasma cell-free DNA from ER-positive breast cancer patients.

Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, Tomiguchi M, Sueta A, Murakami K, Omoto Y, Iwase H.

Oncotarget. 2017 Jun 14;8(32):52142-52155. doi: 10.18632/oncotarget.18479. eCollection 2017 Aug 8.

9.

Proteomics analysis to reveal biological pathways and predictive proteins in the survival of high-grade serous ovarian cancer.

Xie H, Wang W, Sun F, Deng K, Lu X, Liu H, Zhao W, Zhang Y, Zhou X, Li K, Hou Y.

Sci Rep. 2017 Aug 29;7(1):9896. doi: 10.1038/s41598-017-10559-9.

10.

Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.

Toomey S, Eustace AJ, Fay J, Sheehan KM, Carr A, Milewska M, Madden SF, Teiserskiene A, Kay EW, O'Donovan N, Gallagher W, Grogan L, Breathnach O, Walshe J, Kelly C, Moulton B, Kennedy MJ, Gullo G, Hill AD, Power C, Duke D, Hambly N, Crown J, Hennessy BT.

Breast Cancer Res. 2017 Jul 27;19(1):87. doi: 10.1186/s13058-017-0883-9.

11.

Novel therapeutic strategies in the treatment of triple-negative breast cancer.

Oualla K, El-Zawahry HM, Arun B, Reuben JM, Woodward WA, Gamal El-Din H, Lim B, Mellas N, Ueno NT, Fouad TM.

Ther Adv Med Oncol. 2017 Jul;9(7):493-511. doi: 10.1177/1758834017711380. Epub 2017 Jun 13. Review.

12.

Emerging use of everolimus in the treatment of neuroendocrine tumors.

Gajate P, Martínez-Sáez O, Alonso-Gordoa T, Grande E.

Cancer Manag Res. 2017 Jun 20;9:215-224. doi: 10.2147/CMAR.S113382. eCollection 2017. Review.

13.

Molecular characterization of breast cancer cell lines through multiple omic approaches.

Smith SE, Mellor P, Ward AK, Kendall S, McDonald M, Vizeacoumar FS, Vizeacoumar FJ, Napper S, Anderson DH.

Breast Cancer Res. 2017 Jun 5;19(1):65. doi: 10.1186/s13058-017-0855-0.

14.

Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer.

Pierobon M, Ramos C, Wong S, Hodge KA, Aldrich J, Byron S, Anthony SP, Robert NJ, Northfelt DW, Jahanzeb M, Vocila L, Wulfkuhle J, Gambara G, Gallagher RI, Dunetz B, Hoke N, Dong T, Craig DW, Cristofanilli M, Leyland-Jones B, Liotta LA, O'Shaughnessy JA, Carpten JD, Petricoin EF.

Clin Cancer Res. 2017 Aug 15;23(16):4919-4928. doi: 10.1158/1078-0432.CCR-16-2656. Epub 2017 Apr 26.

15.

Immunocompetent mouse allograft models for development of therapies to target breast cancer metastasis.

Yang Y, Yang HH, Hu Y, Watson PH, Liu H, Geiger TR, Anver MR, Haines DC, Martin P, Green JE, Lee MP, Hunter KW, Wakefield LM.

Oncotarget. 2017 May 9;8(19):30621-30643. doi: 10.18632/oncotarget.15695.

16.

The genetic variants in the PTEN/PI3K/AKT pathway predict susceptibility and CE(A)F chemotherapy response to breast cancer and clinical outcomes.

Li X, Zhang R, Liu Z, Li S, Xu H.

Oncotarget. 2017 Mar 21;8(12):20252-20265. doi: 10.18632/oncotarget.15690.

17.

Comparison of the PI3KCA pathway in circulating tumor cells and corresponding tumor tissue of patients with metastatic breast cancer.

Bredemeier M, Kasimir-Bauer S, Kolberg HC, Herold T, Synoracki S, Hauch S, Edimiris P, Bankfalvi A, Tewes M, Kimmig R, Aktas B.

Mol Med Rep. 2017 May;15(5):2957-2968. doi: 10.3892/mmr.2017.6415. Epub 2017 Mar 30.

18.

Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome.

Aure MR, Vitelli V, Jernström S, Kumar S, Krohn M, Due EU, Haukaas TH, Leivonen SK, Vollan HK, Lüders T, Rødland E, Vaske CJ, Zhao W, Møller EK, Nord S, Giskeødegård GF, Bathen TF, Caldas C, Tramm T, Alsner J, Overgaard J, Geisler J, Bukholm IR, Naume B, Schlichting E, Sauer T, Mills GB, Kåresen R, Mælandsmo GM, Lingjærde OC, Frigessi A, Kristensen VN, Børresen-Dale AL, Sahlberg KK; OSBREAC.

Breast Cancer Res. 2017 Mar 29;19(1):44. doi: 10.1186/s13058-017-0812-y.

19.

Tumor burden monitoring using cell-free tumor DNA could be limited by tumor heterogeneity in advanced breast cancer and should be evaluated together with radiographic imaging.

García-Saenz JA, Ayllón P, Laig M, Acosta-Eyzaguirre D, García-Esquinas M, Montes M, Sanz J, Barquín M, Moreno F, Garcia-Barberan V, Díaz-Rubio E, Caldes T, Romero A.

BMC Cancer. 2017 Mar 22;17(1):210. doi: 10.1186/s12885-017-3185-9.

20.

Genome-independent hypoxic repression of estrogen receptor alpha in breast cancer cells.

Padró M, Louie RJ, Lananna BV, Krieg AJ, Timmerman LA, Chan DA.

BMC Cancer. 2017 Mar 20;17(1):203. doi: 10.1186/s12885-017-3140-9.

Supplemental Content

Support Center